- NervGen Pharma (NGEN) completes the dosing of all subjects in the Phase 1 clinical trial of proprietary drug candidate NVG-291
- Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023
- NVG-291 has been demonstrated to promote neural repair mechanisms, including axonal regeneration, remyelination and plasticity
- NervGen is a clinical-stage biotech company
- NervGen (NGEN) is down over 2.50 per cent, trading at C$1.94 at 12:49 pm EST
NervGen Pharma (NGEN) phase 1 subjects in its clinical trial have completed dosing.
NVG-291 is a therapeutic peptide derived from the intracellular domain of the receptor protein tyrosine phosphatase sigma (PTPσ)
The plan in the future is to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury in Q3 2023.
NVG-291 results
Results have been encouraging, and a plan to evaluate the drug candidate’s efficacy, NVG-291 versus placebo in two cohorts is on the way.
In preclinical spinal cord injury studies, NervGen’s NVG-291 has been demonstrated to promote neural repair mechanisms, including axonal regeneration, remyelination and plasticity.
Bill Radvak, NervGen’s Executive Chairman and Interim CEO, is happy about the results in addition to the completion of the dosing session.
“As we have stated previously, the doses of NVG-291 administered in the multiple-dose portion of the study exceed the highest corresponding doses that resulted in significant functional improvements in animal models of acute and chronic spinal cord injury.”
“We now look forward to initiating our Phase 1b/2a clinical trial in spinal cord injury expected by mid-2023,” added Radvak.
Even Daniel Mikol, NervGen’s Chief Medical Officer, added his two cents on the matter and what process was taken. “The safety of subjects was evaluated throughout the treatment phase and through a final scheduled follow-up visit occurring one week after the final dose.”
“[…] we plan to evaluate efficacy using clinical outcome measures and objective electrophysiological measures that provide information about motor recovery,” concluded Mikol.
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic targeting pathogenic mechanism that interferes with nervous system repair.
NervGen is a clinical-stage biotech company.
NervGen (NGEN) is down over 2.50 per cent, trading at C$1.94 at 12:49 pm EST.